Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
NHANES 1 (µg/L) 2013 - 2014 |
|
Children and Adults |
||||||
NCEH/Division of Laboratory Sciences* Contact: Dr. Antonia Calafat |
Per- and Poly-fluoroalkyl Substances (PFAS) |
Yes |
Serum |
1 ml (for all PFAS); 1 ml reserve (for future PFAS analyses) |
Age Group (years): |
50th to 95th % |
perfluorooctanoic acid (PFOA)‡ |
3-5: 6-11: 12-19: 20+: |
1.80 – 5.58 1.94 – 3.84 1.67 – 3.47 2.07 – 5.60 |
||||
n-PFOA - linear isomer |
3-5: 6-11: 12-19: 20+: |
1.72 – 5.32 1.84 – 3.77 1.60 – 3.40 2.00 – 5.40 |
||||
Sb-PFOA - serum branched isomer |
3-5: 6-11: 12-19: 20+: |
< LOD – 0.280 < LOD – 0.230 < LOD – 0.200 < LOD – 0.200 |
||||
perfluorooctane sulfonic acid, (PFOS)‡ |
3-5: 6-11: 12-19: 20+: |
3.41 – 8.82 4.02 – 12.4 3.60 – 9.30 5.60 – 19.5 |
||||
n-PFOS – linear isomer |
3-5: 6-11: 12-19: 20+: |
2.11 – 6.19 2.65 – 8.41 2.70 – 7.10 3.70 – 15.1 |
||||
Sm-PFOS – serum branched |
3-5: 6-11: 12-19: 20+: |
1.00 – 3.60 1.41 – 4.25 1.00 – 2.30 1.60 – 5.30 |
||||
Limit of detection (LOD, see Data Analysis section) for Survey year 13-14 is 0.1. < LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample.
1 CDC. 2018. 2013-2014 NHANES 50th to 95th percentiles among children 12-19 years and adults 20+ years old from the Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, March 2018. Accessed April 13, 2018 at (https://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Volume1_Mar2018.pdf).
‡ See Calculation of PFOS and PFOA as the Sum of Isomers for additional information in March 2018 Updated Tables.
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
NHANES 1 (µg/L) 2013 - 2014 |
|
Children and Adults |
||||||
NCEH/Division of Laboratory Sciences* Contact: Dr. Antonia Calafat |
Per- and Poly-fluoroalkyl Substances (PFAS) (continued) |
Yes |
Serum |
1 ml (for all PFAS); 1 ml reserve (for future PFAS analyses) |
Age Group (years): |
50th to 95th % |
perfluorohexane sulfonic acid (PFHxS) |
3-5: 6-11: 12-19: 20+: |
0.740 – 1.62 0.850 – 4.14 1.10 – 6.30 1.40 – 5.50 |
||||
perfluorooctane sulfonamide (PFOSA) |
3-5: 6-11: 12-19: 20+: |
< LOD – 0.110 < LOD - < LOD n/a ‡ n/a ‡ |
||||
2-(N-methyl-perfluorooctane sulfonamido) acetic acid (Me-PFOSAA) |
3-5: 6-11: 12-19: 20+: |
0.110 – 1.02 0.110 – 0.940 0.100 – 0.600 < LOD – 0.600 |
||||
2-(N-ethyl-perfluorooctane sulfonamido) acetic acid (Et-PFOSAA) |
3-5: 6-11: 12-19: 20+: |
< LOD - < LOD < LOD - < LOD n/a ‡ n/a ‡ |
||||
perfluorobutane sulfonic acid (PFBS) |
3-5: 6-11: 12-19: 20+: |
< LOD - < LOD < LOD – 0.130 < LOD - < LOD < LOD - < LOD |
||||
perfluoroheptanoic acid (PFHpA) |
3-5: 6-11: 12-19: 20+: |
< LOD – 0.310 < LOD – 0.170 < LOD – 0.200 < LOD – 0.100 |
||||
Limit of detection (LOD, see Data Analysis section) for Survey year 13-14 is 0.1. < LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. ‡ Not measured after Survey Years 2011-2012.
1 CDC. 2018. 2013-2014 NHANES 50th to 95th percentiles among children 12-19 years and adults 20+ years old from the Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, March 2018. Accessed April 13, 2018 at (https://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Volume1_Mar2018.pdf).
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
NHANES 1 (µg/L) 2013 - 2014 |
||
Children and Adults |
|||||||
NCEH/Division of Laboratory Sciences* Contact: Dr. Antonia Calafat |
Per- and Poly-fluoroalkyl Substances (PFAS) (continued) |
Yes |
Serum |
1 ml (for all PFAS); 1 ml reserve (for future PFAS analyses) |
Age Group (years): |
50th to 95th % |
|
perfluorononanoic acid (PFNA) |
3-5: 6-11: 12-19: 20+: |
0.620 – 3.49 0.750 – 3.19 0.500 – 2.00 0.700 – 2.00 |
|||||
perfluorodecanoic acid (PFDA) |
3-5: 6-11: 12-19: 20+: |
0.100 – 0.370 < LOD – 0.350 0.100 – 0.400 0.193 – 0.800 |
|||||
perfluoroundecanoic acid (PFUnDA) |
3-5: 6-11: 12-19: 20+: |
< LOD – 0.370 < LOD – 0.250 < LOD – 0.200 < LOD – 0.500 |
|||||
perfluorododecanoic acid (PFDoA) |
3-5: 6-11: 12-19: 20+: |
< LOD - < LOD < LOD - < LOD < LOD – 0.200 < LOD – 0.200 |
|||||
Laboratory and Contact |
Proposed Biospecimen Bank for Future Analytes |
* CLIA Cert. |
Matrix |
Volume |
NHANES TBD (µg/L) 20xx – 20xx |
||
Children and Adults |
|||||||
NCEH/Division of Laboratory Sciences* Contact: Dr. Antonia Calafat |
Per- and Poly-fluoroalkyl Substances (PFAS) |
Yes |
Spot Urine (morning void) |
1 ml (for PFAS); 15 ml for creatinine/or specific gravity) |
Age Group: |
50th to 95th % |
|
To be determined (TBD) when analytical methods are developed (Including but not limited to the following 18 analytes: PFOA [n-PFOA;, Sb-PFOA], PFOA [n-PFOS, Sm-PFOS], PFHxS, PFBS, PFHpA, PFNA, PFDA, PFUnDA, PFPrS, PFHpS, PFBA, PFPeA, PFHxA, HFPO-DA (GenX), DONA, 9Cl-PF3ONS) |
3-5: 6-11: 12-19: 20+: |
TBD TBD TBD TBD |
|||||
Creatinine (for urinary creatinine correction; may be contracted) |
TBD |
||||||
Limit of detection (LOD, see Data Analysis section) for Survey year 13-14 is 0.1. < LOD means less than the limit of detection, which may vary for some chemicals by year and by individual sample. ‡ Not measured after Survey Years 2011-2012.
1 CDC. 2018. 2013-2014 NHANES 50th to 95th percentiles among children 12-19 years and adults 20+ years old from the Fourth National Report on Human Exposure to Environmental Chemicals, Updated Tables, March 2018. Accessed April 13, 2018 at (https://www.cdc.gov/exposurereport/pdf/FourthReport_UpdatedTables_Volume1_Mar2018.pdf).
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
Reportable Range, Guidelines, Critical Values Reference ranges will be updated when commercial lab is selected. |
Children and Adults |
|||||
Commercial Laboratory (to be determined)* Contact: |
Lipids |
Yes |
Serum |
0.5 ml (for all) |
|
Total cholesterol, fasting |
Coronary Heart Disease Risk (CHD)1 Adult, 18+ years: Desirable: <200 mg/dL Borderline High: 200-239 mg/dL High: ≥240 mg/dL
Child, 2-17 years: Acceptable: <170 mg/dL Borderline high: 170-199 mg/dL High: ≥200 mg/dL |
||||
Triglycerides, fasting |
CHD Risk1 Adult, 18+ years: Normal: <150 mg/dL Borderline High: 150-199 mg/dL High: 200-499 mg/dL Very High: ≥500 mg/dL
Critical Value: >1,000 mg/dL
Child, 2-9 years: Acceptable: <75 mg/dL Borderline high: 75-99 mg/dL High: ≥100 mg/dL
Child, 10-17 years: Acceptable: <90 mg/dL Borderline high: 90-129 mg/dL High: > or =130 mg/dL |
||||
Low Density Lipoprotein (LDL), fasting |
CHD Risk1 Adult, 18+ years: Desirable: <100 mg/dL Above Desirable: 100-129 mg/dL Borderline high: 130-159 mg/dL High: 160-189 mg/dL Very high: ≥190 mg/dL
Child, 2-17 years: Acceptable: <110 mg/dL Borderline high: 110-129 mg/dL High: ≥130 mg/dL |
||||
High Density Lipoprotein (HDL), fasting |
CHD Risk1 Adult, 18+ years: Males: ≥40 mg/dL Females: ≥50 mg/dL
Child, 2-17 years: Low: <40 mg/dL Borderline low: 40-45 mg/dL Acceptable: > 45 mg/dL |
||||
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
Reportable Range, Guidelines, Critical Values Reference ranges will be updated when commercial lab is selected. |
||||||||||||||||||||||||||
Children and Adults |
|||||||||||||||||||||||||||||||
Commercial Laboratory (to be determined)* Contact: |
Uric Acid |
Yes |
Serum |
1 ml |
Males2 ≤ 8.0 mg/dL Females ≤ 6.1 mg/dL |
||||||||||||||||||||||||||
Creatinine (to estimate glomerular filtration rate [eGFR]) |
Males3 1-2 years: 0.1-0.4 mg/dL 3-4 years: 0.1-0.5 mg/dL 5-9 years: 0.2-0.6 mg/dL 10-11 years: 0.3-0.7 mg/dL 12-13 years: 0.4-0.8 mg/dL 14-15 years: 0.5-0.9 mg/dL > or =16 years: 0.8-1.3 mg/dL Reference values have not been established for patients that are <12 months of age.
Females 1-3 years: 0.1-0.4 mg/dL 4-5 years: 0.2-0.5 mg/dL 6-8 years: 0.3-0.6 mg/dL 9-15 years: 0.4-0.7 mg/dL > or =16 years: 0.6-1.1 mg/dL Reference values have not been established for patients that are <12 months of age.
ESTIMATED GFR >60 mL/min/BSA Note: eGFR results will not be calculated for patients <18 or >70 years old. |
||||||||||||||||||||||||||||||
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
Reportable Range, Guidelines, Critical Values Reference ranges will be updated when commercial lab is selected. |
||||||||||||||||||||||||||
Children and Adults |
|||||||||||||||||||||||||||||||
Commercial Laboratory (to be determined)* Contact: |
Thyroid Hormones |
Yes |
Serum |
0.5 ml |
|
||||||||||||||||||||||||||
Thyroid Stimulating Hormone (TSH) |
0.30-3.0 mIU/L 4 |
||||||||||||||||||||||||||||||
Free Total Thyroxine (Free T4) |
0.8-2.0 ng/dL |
||||||||||||||||||||||||||||||
Total Thyroxine (TT4) |
4.5-12.5 µg/dL |
||||||||||||||||||||||||||||||
Total Triiodothyronine (TT3) |
80-180 ng/dL |
||||||||||||||||||||||||||||||
Commercial Laboratory (to be determined)* Contact: |
Liver Tests |
Yes |
Serum |
0.5 ml standard tests; 1 ml CK18
|
|
||||||||||||||||||||||||||
Alanine transaminase (ALT) |
15-65 U/L 5 |
||||||||||||||||||||||||||||||
Aspartate transaminase (AST) |
5-40 U/L |
||||||||||||||||||||||||||||||
Alkaline phosphatase (ALP) |
Female: 50-136 U/L; Male: 40-136 U/L |
||||||||||||||||||||||||||||||
Gamma-glutamyltransferase (GGT) |
Female 5-55 U/L; Male 5-85 U/L |
||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||
Albumin (Alb) |
3.4-5.0 g/dL
Critical Value: <1.5 g/dL Critical Value: >7.9 g/dL |
||||||||||||||||||||||||||||||
Total bilirubin (TBIL) |
0.0 – 1.0 mg/dL
Critical Value: >12.9 mg/dL |
||||||||||||||||||||||||||||||
Direct bilirubin (Conjugated Bilirubin) |
0.0-0.3 mg/dL |
||||||||||||||||||||||||||||||
|
|
||||||||||||||||||||||||||||||
Non-alcoholic fatty liver disease (NAFLD)/steatohepatitis |
|
||||||||||||||||||||||||||||||
Cytokeratin 18 M30 (CK-18 M30) Cytokeratin 18 M65 (CK-18 M65) |
No evident liver disease: M30 <200 U/L and M65 <300 U/L TASH: M30<200 U/L and M65 >300 U/L Other liver disease: M30: >200 U/L |
||||||||||||||||||||||||||||||
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
Reportable Range, Guidelines, Critical Values Reference ranges will be updated when commercial lab is selected. |
||||||||||||||||||||||||||
Children and Adults |
|||||||||||||||||||||||||||||||
Commercial Laboratory (to be determined)* Contact: |
Sex Hormones |
Yes |
Serum |
1 ml |
|
||||||||||||||||||||||||||
Testosterone |
Males6 4-9 years: <7-20 ng/dL 10-11 years: <7-130 ng/dL 12-13 years: <7-800 ng/dL 14 years: <7-1,200 ng/dL 15-16 years: 100-1,200 ng/dL 17-18 years: 300-1,200 ng/dL ≥19 years: 240-950 ng/dL
Females 4-9 years: <7-20 ng/dL 10-11 years: <7-44 ng/dL 12-16 years: <7-75 ng/dL 17-18 years: 20-75 ng/dL ≥19 years: 8-60 ng/dL |
||||||||||||||||||||||||||||||
Estradiol |
CHILDREN7 Males
Females
ADULTS Males: 10-40 pg/mL Females Premenopausal: 15-350 pg/mL** Postmenopausal: <10 pg/mL **E2 levels vary widely through the menstrual cycle. |
||||||||||||||||||||||||||||||
Sex hormone-binding globulin (SHBG) |
CHILDREN8 Males
Females
ADULTS Males: 10-57 nmol/L Females (non-pregnant): 18-144 nmol/L |
||||||||||||||||||||||||||||||
Follicle stimulating hormone (FSH) |
Males9 4-6 years: < or =6.7 IU/L 7-8 years: < or =4.1 IU/L 9-10 years: < or =4.5 IU/L 11 years: 0.4-8.9 IU/L 12 years: 0.5-10.5 IU/L 13 years: 0.7-10.8 IU/L 14 years: 0.5-10.5 IU/L 15 years: 0.4-18.5 IU/L 16 years: < or =9.7 IU/L 17 years: 2.2-12.3 IU/L ≥18 years: 1.0-18.0 IU/L Females 15 days-6 years: < or =3.3 IU/L 7-8 years: < or =11.1 IU/L 9-10 years: 0.4-6.9 IU/L 11 years: 0.4-9.0 IU/L 12 years: 1.0-17.2 IU/L 13 years: 1.8-9.9 IU/L 14-16 years: 0.9-12.4 IU/L 17 years: 1.2-9.6 IU/L ≥18 years: Premenopausal Follicular: 3.9-8.8 IU/L Midcycle: 4.5-22.5 IU/L Luteal: 1.8-5.1 IU/L Postmenopausal: 16.7-113.6 IU/L |
||||||||||||||||||||||||||||||
Insulin-like growth factor (IGF-1) |
|
||||||||||||||||||||||||||||||
Laboratory and Contact |
Analyte |
* CLIA Cert. |
Matrix |
Volume |
Reportable Range, Guidelines, Critical Values Reference ranges will be updated when commercial lab is selected. |
||
Children and Adults |
|||||||
Commercial Laboratory (to be determined)* Contact: |
Immune Function |
Yes |
Serum |
2 ml |
|
||
Ig A, Ig G, Ig M, Ig E |
|
||||||
Commercial Laboratory (to be determined)* Contact: |
Glycemic Parameters |
Yes |
|
|
|
||
Glycosylated hemoglobin (HbA1c) |
Whole Blood EDTA |
1 ml; plus 1 ml reserve |
Diabetes Risk10 Normal: <5.7% Increased Risk Diabetes: 5.7-6.4% Diabetes: ≥6.5% (confirmation required) |
||||
Glucose, fasting, 8-hour |
Serum |
1 ml Glucose/ Insulin; 1 ml antibodies |
|
||||
Insulin |
<17 µU/ml 8 |
||||||
Pro-insulin |
3.6-22 pmol/L8 |
||||||
C-peptide |
1.1-4.4 ng/mL8 |
||||||
Glutamate Decarboxylase -65 (Anti-GAD 65) |
Negative Antibody: DK≤33 8 Positive Antibody: DK>33 |
||||||
Thyrosine Phosphatase-like Protein Autoantibodies (Anti-IA2) |
Negative Antibody: DK<5 8 Positive Antibody: DK≥5 |
||||||
Children Only |
|||||||
Commercial Laboratory (to be determined)* Contact: |
Antibodies to measles, mumps, rubella, tetanus, and diphtheria |
Yes |
Serum |
1 ml |
|
||
Child Total |
Serum - 11ml Whole Blood – 2 ml Urine – 16 ml Red Top 3 x10 ml EDTA Lavender Top 3 ml |
||||||
Adults Only |
|||||
Commercial Laboratory (to be determined)* Contact: |
Autoimmune Parameters |
Yes |
Serum |
2 ml (for all) |
|
Rheumatoid Factor (RF) |
< 15 IU/mL11 |
||||
Antinuclear Antibody (ANA) screen |
< or =1.0 U (negative)12 1.1-2.9 U (weakly positive) 3.0-5.9 U (positive) > or =6.0 U (strongly positive) |
||||
Antinuclear Antibody (ANA) titer |
|
||||
|
|
|
|
|
|
|
Inflammatory Cytokines |
|
|
|
|
|
Interleukin 1-β (IL-1β), IL-4, IL-6, IL-8, IL-12, monocyte chemotactic protein-1 (MCP-1), tumor necrosis factor α (TNFα), leptin, adiponectin, resistin, plasminogen activator inhibitor-1 (PAI-1). |
No |
Serum |
2 ml |
Clinical reference levels not established. |
|
|
|
|
|
|
Adult Total |
Serum – 15 ml Whole Blood – 2 ml Urine – 16 ml Red Top 4 x 10 ml EDTA Lavender Top 3 ml |
||||
4 University of Southern California Clinical Laboratories Endocrine Services.
5 University of Louisville Department of Medicine, Gastroenterology (updated 14 October 2015).
10 American Diabetes Association. Standards of Medical Care in Diabetes - 2011. Diabetes Care. January 2011;34(Supplement 1):S11-S61 (subject to periodic update).
| File Type | application/vnd.openxmlformats-officedocument.wordprocessingml.document |
| Author | Stephanie Davis |
| File Modified | 0000-00-00 |
| File Created | 2021-01-13 |